LOBEF (Lobe Sciences) EBITDA Margin %: 0.00% (As of Feb. 2026)


What is Lobe Sciences EBITDA Margin %?

Lobe Sciences LOBEF EBITDA Margin % is 0.00% as of Feb. 2026. The stock has 2 warning signs investors should review. Among 945 Biotechnology companies, Lobe Sciences ranks worse than 105820% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Lobe Sciences's EBITDA for the three months ended in Feb. 2026 was $-1.74 Mil. Lobe Sciences's Revenue for the three months ended in Feb. 2026 was $0.00 Mil. Therefore, Lobe Sciences's EBITDA margin for the quarter that ended in Feb. 2026 was 0.00%.

Lobe Sciences  (OTCPK:LOBEF) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Lobe Sciences EBITDA Margin % Related Terms

Lobe Sciences EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Lobe Sciences's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lobe Sciences EBITDA Margin % Chart

Lobe Sciences Annual Data
Trend Dec16 Dec17 Dec18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -525.48 -3,014.00 0.00

Lobe Sciences Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

LOBEF vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, Lobe Sciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lobe Sciences EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lobe Sciences's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Lobe Sciences's EBITDA Margin % falls into.


Lobe Sciences EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Lobe Sciences's EBITDA Margin % for the fiscal year that ended in Aug. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Aug. 2025 )/Revenue (A: Aug. 2025 )
=-3.091/0
= %

Lobe Sciences's EBITDA Margin % for the quarter that ended in Feb. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Feb. 2026 )/Revenue (Q: Feb. 2026 )
=-1.737/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Lobe Sciences (LOBEF) has a EBITDA Margin % of 0.00% as of Feb. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Lobe Sciences and its competitors. According to the industry distribution chart, Lobe Sciences ranks #999999 out of 945 companies in the Biotechnology industry.
Is Lobe Sciences' EBITDA Margin % too high?
Lobe Sciences' current EBITDA Margin % is 0.00%. Based on the distribution chart, Lobe Sciences ranks #999999 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Lobe Sciences' EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lobe Sciences ranks #999999 out of 945 companies for EBITDA Margin %. This places Lobe Sciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Lobe Sciences and its competitors. Lobe Sciences's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lobe Sciences stock overvalued right now?
Lobe Sciences (LOBEF) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Lobe Sciences (LOBEF), the current EBITDA Margin % is 0.00% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lobe Sciences Business Description

Other Exchanges LOBE:GermanyLOBE:Canada
Address 1771 Robson Street, No. 1614, Vancouver, BC, CAN, V6G 3B7
Lobe Sciences Ltd is a biopharmaceutical company focused on using lipid technology that develop therapies for orphan and rare diseases. It commercializes Altemia MF, a medical food intended to address nutritional deficiencies associated with sickle cell disease. Through its subsidiaries, the company also holds a majority interest in the development of Conjugated Psilocin for potential use in neurological and psychiatric indications. The company operates in one reportable segment, being the biopharmaceutical development of new medicines.